citric acid, anhydrous has been researched along with Hyperphosphatemia in 4 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since hyperphosphatemia is an established risk factor for not only secondary hyperparathyroidism, but also cardiovascular mortality in these patients, the adequate control of serum phosphorus is necessary." | 2.45 | [Novel phosphate binders under development]. ( Akizawa, T; Mizobuchi, M; Sanada, D, 2009) |
| "Iron-based Pi-binders are used to treat hyperphosphatemia in CKD patients." | 1.51 | High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs. ( Block, GA; Bulfamante, G; Ciceri, P; Cozzolino, M; Falleni, M; Martinelli, C; Messa, P; Tosi, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P | 1 |
| Falleni, M | 1 |
| Tosi, D | 1 |
| Martinelli, C | 1 |
| Bulfamante, G | 1 |
| Block, GA | 1 |
| Messa, P | 1 |
| Cozzolino, M | 1 |
| Quiñones, H | 1 |
| Hamdi, T | 1 |
| Sakhaee, K | 1 |
| Pasch, A | 1 |
| Moe, OW | 1 |
| Pak, CYC | 1 |
| Mizobuchi, M | 1 |
| Sanada, D | 1 |
| Akizawa, T | 1 |
| Adamcewicz, M | 1 |
| Bearelly, D | 1 |
| Porat, G | 1 |
| Friedenberg, FK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Colon Preparation With 2-Litre Polyethylene Glycol (PEG) Split-dose in Combination With Lubiprostone Versus 4-Litre Polyethylene Glycol (PEG) Split-dose: a Randomized Controlled Trial[NCT04138004] | Phase 4 | 140 participants (Actual) | Interventional | 2019-12-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for citric acid, anhydrous and Hyperphosphatemia
| Article | Year |
|---|---|
[Novel phosphate binders under development].
Topics: Bile Acids and Salts; Chronic Disease; Citric Acid; Clinical Trials as Topic; Drug Design; Ferrous C | 2009 |
Mechanism of action and toxicities of purgatives used for colonoscopy preparation.
Topics: Ascorbic Acid; Calcium Phosphates; Cathartics; Citric Acid; Colonic Neoplasms; Colonoscopy; Humans; | 2011 |
1 trial available for citric acid, anhydrous and Hyperphosphatemia
| Article | Year |
|---|---|
Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Topics: Acid-Base Equilibrium; Acidosis; Aged; Bicarbonates; Biomarkers; Calcium Citrate; Cardiovascular Dis | 2019 |
1 other study available for citric acid, anhydrous and Hyperphosphatemia
| Article | Year |
|---|---|
High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs.
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Chondrocytes; Citric Acid; Extracellular Mat | 2019 |